Artios Pharma develops oral small‑molecule inhibitors that target DNA damage response pathways in solid tumors, using its DcoDeR platform to align drugs with biomarker‑defined patient groups. Its lead ATR inhibitor alnodesertib, which has FDA Fast Track status for ATM‑deficient colorectal cancer, is intended to boost low‑dose chemotherapy, while the Polθ inhibitor ART6043 blocks micro‑homology‑mediated end joining and is being evaluated alone and with PARP inhibitors. The company provides combination‑ready, first‑in‑class DDR agents for oncology clinicians and pharmaceutical partners.
Funding
$152.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
TCFounders
Product
Problem
Patients with advanced solid tumors often have limited treatment options because existing DNA‑damaging therapies are non‑selective, cause significant toxicity, and many tumors develop resistance to current DDR‑targeted agents such as PARP inhibitors. This leaves a substantial unmet need for therapies that can exploit specific DNA damage response vulnerabilities while sparing normal tissue.
Solution
Artios Pharma applies a DNA Damage Response (DDR)‑focused drug discovery strategy to create oral, small‑molecule inhibitors that selectively cripple cancer‑cell repair mechanisms. The proprietary DcoDeR platform integrates comprehensive DDR pathway biology with biomarker‑driven patient stratification to identify optimal drug combinations. Its lead ATR inhibitor, alnodesertib, blocks replication‑stress signaling, enhancing the efficacy of low‑dose chemotherapy and has earned FDA Fast Track designation for ATM‑deficient colorectal cancer. The Polθ inhibitor ART6043 disrupts micro‑homology‑mediated end joining, a backup repair route in DDR‑deficient tumors, and is being evaluated both as monotherapy and in combination with the PARP inhibitor olaparib. By targeting distinct DDR nodes, Artios aims to deliver first‑ and best‑in‑class agents that provide durable responses across a broad spectrum of hard‑to‑treat cancers.
Target Audience
Primary customers are oncology clinicians, academic investigators, and pharmaceutical partners developing therapies for solid tumors with high unmet need, particularly those seeking DDR‑targeted combination regimens.
Features
- Selective, orally bioavailable ATR inhibitor (alnodesertib) that induces DNA damage selectively in replication‑stressed tumor cells while preserving healthy tissue.
- FDA Fast Track designation for alnodesertib + low‑dose irinotecan in ATM‑negative metastatic colorectal cancer, supporting accelerated development.
- Polθ inhibitor (ART6043) that blocks the polymerase domain of DNA polymerase theta, inhibiting micro‑homology‑mediated end joining in DDR‑deficient cancers.
- Combination‑ready design: alnodesertib synergizes with chemotherapy; ART6043 is being paired with PARP inhibitor olaparib and explored with radiotherapy and immuno‑oncology agents.
- DcoDeR platform leverages integrated DDR pathway mapping, biomarker analytics, and disease positioning to guide candidate selection, dosing, and patient stratification.
- First‑ and best‑in‑class potential across multiple solid‑tumor indications, supported by preclinical potency and early‑phase clinical safety data.
- Oral dosing regimen enables outpatient administration and facilitates integration into existing treatment schedules.
- Robust translational pipeline with ongoing Phase 1/2a studies and planned Phase 2 expansions to accelerate clinical readouts.